Lumexa Imaging Holdings, Inc. (LMRI) Key Metrics
LMRI valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.04B
- Enterprise value
- $1.88B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.0
- Price / book
- 1.6
- EV / EBITDA
- 14.2
- Dividend yield
- —
- Beta
- —
LMRI key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsLMRI returns How much profit the business earns on the capital it uses.
LMRI per-share figures Results divided by the shares outstanding at year-end.
LMRI financial health Debt, liquidity and how easily interest is covered.
LMRI efficiency & capital use Working capital cycle and where the cash goes.
LMRI valuation history
LMRI returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LMRI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LMRI cash returned to shareholders
LMRI price vs earnings per share
LMRI key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Valuation | |||
| Market capitalization | $1.31B | — | — |
| Enterprise value | $2.22B | — | — |
| Price / sales | 1.3 | — | — |
| Price / book | 2.2 | — | — |
| Price / operating cash flow | 76.9 | — | — |
| EV / sales | 2.2 | — | — |
| EV / EBITDA | 15.6 | — | — |
| Earnings yield | −3.6% | — | — |
| Free cash flow yield | −0.5% | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — |
| Share price at fiscal year-end | $18.50 | — | — |
| Per share | |||
| Revenue per share | $14.41 | $10.03 | $9.90 |
| Earnings per share | −$0.66 | −$1.00 | −$1.29 |
| Operating cash flow per share | $0.24 | $0.43 | $0.40 |
| Free cash flow per share | −$0.09 | $0.14 | $0.14 |
| Cash per share | $0.83 | $0.28 | $0.21 |
| Book value per share | $8.26 | $1.71 | $2.10 |
| Tangible book value per share | −$3.70 | −$7.34 | −$7.06 |
| Capex per share | $0.33 | $0.29 | $0.25 |
| Debt per share | $13.56 | $13.85 | $13.80 |
| Shares outstanding | 71.0M | 94.6M | 94.6M |
| Change in shares outstanding | −24.9% | 0.0% | — |
| Returns & profitability | |||
| Return on equity (ROE) | −12.6% | −52.3% | −61.6% |
| Return on invested capital (ROIC) | 1.4% | 3.0% | 1.2% |
| Return on assets (ROA) | −2.7% | −5.6% | −7.3% |
| Return on tangible assets | −5.1% | −11.5% | −15.2% |
| Free cash flow margin | −0.6% | 1.4% | 1.4% |
| Financial health | |||
| Total debt | $962.5M | $1.31B | $1.30B |
| Cash & short-term investments | $58.8M | $26.1M | $20.2M |
| Net debt | $903.7M | $1.28B | $1.28B |
| Debt / equity | 1.64 | 8.10 | 6.58 |
| Debt / assets | 0.55 | 0.78 | 0.78 |
| Net debt / EBITDA | 6.38 | 11.26 | 13.58 |
| Current ratio | 1.27 | 0.99 | 1.04 |
| Quick ratio | 1.27 | 0.99 | 1.04 |
| Interest coverage | 0.2 | 0.4 | 0.2 |
| Working capital | $48.1M | −$1.1M | $5.7M |
| Invested capital | $1.49B | $1.44B | $1.48B |
| Tangible asset value | −$262.8M | −$693.7M | −$667.5M |
| Net current asset value | −$951.2M | −$1.34B | −$1.31B |
| Graham net-net per share | −$14.18 | −$14.60 | −$14.33 |
| Capital allocation | |||
| Share buybacks (net) | $0 | $0 | $118,000 |
| Dividends + buybacks / free cash flow | — | 0.0% | 0.9% |
| Capex / revenue | 2.3% | 2.9% | 2.6% |
| Capex / operating cash flow | 137.5% | 68.2% | 64.0% |
| Capex / depreciation | 0.42 | 0.49 | 0.33 |
| Stock-based compensation / revenue | 4.1% | 6.0% | 5.9% |
| SG&A / revenue | 8.8% | 7.4% | 5.9% |
| Efficiency | |||
| Days sales outstanding | 51.2 | 51.2 | 50.8 |
| Days payables outstanding | 15.1 | 11.6 | 10.6 |
| Cash conversion cycle (days) | 36.1 | 39.6 | 40.2 |
| Receivables turnover | 7.13 | 7.13 | 7.19 |
| Payables turnover | 24.24 | 31.40 | 34.28 |
| Asset turnover | 0.60 | 0.57 | 0.56 |
| Average receivables | $143.4M | $133.1M | $130.3M |
| Average payables | $37.4M | $27.2M | $24.4M |
| Intangibles / total assets | 48.1% | 51.2% | 51.8% |
Computed from LMRI's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LMRI valuation and financial ratios
Lumexa Imaging earned a return on equity of −12.6% and a return on invested capital of 1.4% in fiscal 2025. It ended the year with $962.5 million of debt and $58.8 million in cash and short-term investments, net debt of $903.7 million.
See the LMRI income statement, the LMRI chart for price history, or the LMRI stock overview for the latest quote and news.
LMRI key metrics FAQ
What is Lumexa Imaging's EV/EBITDA?
Lumexa Imaging's enterprise value was 15.6 times EBITDA at the end of fiscal 2025 (enterprise value $2.2 billion, EBITDA $141.7 million); the current EV/EBITDA is 14.2.
What is Lumexa Imaging's return on equity?
Lumexa Imaging's return on equity (ROE) was −12.6% in fiscal 2025: net income of -$47.1 million on average shareholders' equity of $373.9 million.
What is Lumexa Imaging's ROIC?
Lumexa Imaging's return on invested capital was 1.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Lumexa Imaging have?
Lumexa Imaging had total debt of $962.5 million at the end of fiscal 2025, a debt-to-equity ratio of 1.64 and $903.7 million of net debt (6.38 times EBITDA).
What is Lumexa Imaging's free cash flow yield?
Lumexa Imaging generated -$6.4 million of free cash flow in fiscal 2025, a free cash flow yield of −0.5% on its market value at year-end ($1.3 billion).
What is Lumexa Imaging's current ratio?
Lumexa Imaging's current ratio was 1.27 at the end of fiscal 2025: current assets were 1.27 times current liabilities.